Product Description
A collaboration target with Ionis Pharmaceuticals for cardiometabolic indications, part of wave 1 of the Ionis collaboration, which includes four targets. (Sourced from: https://www.benzinga.com/pressreleases/26/03/g51082647/metagenomi-therapeutics-reports-business-updates-and-full-year-2025-financial-results)
Mechanisms of Action: APOC3 Inhibitor
Novel Mechanism: No
Modality: Gene Therapy
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Metagenomi
Company Location: Western America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Metabolic Syndrome X
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|